Zydus Lifesciences board clears ₹1,100 crore share buyback at ₹1,150 apiece

Zydus Lifesciences Ltd has approved a share buyback proposal aggregating up to ₹1,100 crore through the tender offer mechanism, according to a regulatory filing issued on Monday.

The pharmaceutical major plans to repurchase up to 95,65,217 equity shares having a face value of ₹1 each at a buyback price of ₹1,150 per share. The proposed repurchase size represents nearly 0.95% of the company’s total paid-up equity share capital.

The company has fixed May 29, 2026, as the record date to determine the entitlement and eligibility of shareholders participating in the buyback process.

As per the filing, the buyback size accounts for 15.6% and 3.84% of the aggregate standalone and consolidated paid-up equity capital and free reserves respectively, based on the audited financial statements for FY26.

Zydus Lifesciences stated that the buyback will be conducted on a proportionate basis through the tender offer route in compliance with SEBI Buyback Regulations and provisions of the Companies Act, 2013.

The announcement came alongside the company’s March quarter earnings. Zydus reported consolidated revenue from operations of ₹7,587 crore in Q4 FY26, up 16.2% year-on-year from ₹6,527.9 crore reported in the same quarter last year.

Net profit for the quarter stood at ₹1,272.5 crore compared with ₹1,170.9 crore in the year-ago period. EBITDA came in at ₹2,554 crore during the quarter, while EBITDA margin improved to 33.7% from 32.6% a year earlier.

The company further stated that its board or buyback committee retains the right to revise the buyback price and reduce the number of shares proposed to be bought back, without altering the overall buyback size.